CeriBell (NASDAQ: CBLL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $30.00 to $31.00. They now have a "buy" rating on the stock.
Ceribell Reports Third Quarter 2024 Financial Results
Ceribell Receives Authority to Operate from the U.S. Department of Veterans Affairs
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
CeriBell (NASDAQ: CBLL) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $30.00 price target on the stock.